cilostazol has been researched along with Blood Clot in 56 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to assess the degree of platelet inhibition by adjunctive cilostazol in patients with acute myocardial infarction (AMI) according to hepatic cytochrome P450 2C19 (CYP2C19) genotype." | 9.15 | Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. ( Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Kim, S; Koh, EH; Kwak, CH; Park, JR; Park, KS; Park, Y; Yun, SE, 2011) |
| "We compared the effects of ticlopidine and cilostazol on the prevention of subacute stent thrombosis (SAT) in acute myocardial infarction (AMI) patients with stenting." | 9.11 | Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention. ( Adachi, K; Kataoka, T; Kawata, M; Kuramoto, E; Matsuura, A; Saito, A; Sakamoto, S, 2005) |
| "In this analysis, we aimed to systematically compare stent thrombosis (ST) and its different subtypes following treatment with DAPT (aspirin + clopidogrel) versus TAPT (aspirin + clopidogrel + cilostazol)." | 8.98 | Stent thrombosis associated with drug eluting stents on addition of cilostazol to the standard dual antiplatelet therapy following percutaneous coronary intervention: a systematic review and meta-analysis of published randomized controlled trials. ( Huang, F, 2018) |
| "We conducted a prospective study on patients with cerebral infarction who were treated with cilostazol." | 7.88 | Association of platelet response to cilostazol with clinical outcome and CYP genotype in patients with cerebral infarction. ( Hato, T; Ikeda, Y; Kumon, Y; Yamanouchi, J; Yasukawa, M, 2018) |
| "We evaluate the anti-platelet and anti-thrombotic effects of cilostazol using Multiplate® and PFA-100® in vitro and ex vivo with freshly isolated rat whole blood and in vivo venous and arterial thrombosis models in the same species, in an effort to assess the sensitivity of the whole blood aggregometer assays without potential issues of species differences." | 7.77 | Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100® and Multiplate® whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo. ( Bae, IH; Chung, JH; Jeong, YS; Kim, CW; Lim, KM; Park, JW; Park, YH; Yun, JW, 2011) |
| "These platelets enhance thrombus formation at the sites of endothelial disruption." | 6.43 | Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. ( Goto, S, 2005) |
| "Z-335 (0." | 5.31 | Z-335, a new thromboxane A(2) receptor antagonist, prevents arterial thrombosis induced by ferric chloride in rats. ( Kurimoto, T; Sato, R; Tanaka, T, 2000) |
| "The aim of this study was to assess the degree of platelet inhibition by adjunctive cilostazol in patients with acute myocardial infarction (AMI) according to hepatic cytochrome P450 2C19 (CYP2C19) genotype." | 5.15 | Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. ( Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Kim, S; Koh, EH; Kwak, CH; Park, JR; Park, KS; Park, Y; Yun, SE, 2011) |
| "We compared the effects of ticlopidine and cilostazol on the prevention of subacute stent thrombosis (SAT) in acute myocardial infarction (AMI) patients with stenting." | 5.11 | Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention. ( Adachi, K; Kataoka, T; Kawata, M; Kuramoto, E; Matsuura, A; Saito, A; Sakamoto, S, 2005) |
| "In this analysis, we aimed to systematically compare stent thrombosis (ST) and its different subtypes following treatment with DAPT (aspirin + clopidogrel) versus TAPT (aspirin + clopidogrel + cilostazol)." | 4.98 | Stent thrombosis associated with drug eluting stents on addition of cilostazol to the standard dual antiplatelet therapy following percutaneous coronary intervention: a systematic review and meta-analysis of published randomized controlled trials. ( Huang, F, 2018) |
| " In the last few years, cilostazol, a phosphodiesterase (PDE) 3 inhibitor, has been tested in the setting of acute coronary syndromes: it exerts not only anti-platelet actions, but also pleiotropic effects, including inhibition on neointimal hyperplasia, therefore preventing both stent restenosis and thrombosis." | 4.88 | Cilostazol and primary-PCI: mirage or good alternative? ( Crea, F; D'Amario, D; Porto, I, 2012) |
| " We give an overview of several new antiplatelet agents that are currently investigated in secondary stroke prevention: adenosine 5'-diphosphonate receptor antagonists, cilostazol, sarpogrelate, terutroban and SCH 530348." | 4.86 | Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention. ( Diener, HC; Weber, R, 2010) |
| "Patients on cilostazol were divided into 4 groups according to arterial occlusive disease etiology: (1) atherosclerosis, (2) diabetic angiopathy, (3) embolism/thrombosis, and (4) Buerger disease." | 4.31 | Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol? ( Arslan, K; Can Depboylu, B; Funda Tetik, M; Harmandar, B; Ilhan, G; Istar, H; Yazman, S, 2023) |
| "We conducted a prospective study on patients with cerebral infarction who were treated with cilostazol." | 3.88 | Association of platelet response to cilostazol with clinical outcome and CYP genotype in patients with cerebral infarction. ( Hato, T; Ikeda, Y; Kumon, Y; Yamanouchi, J; Yasukawa, M, 2018) |
| "Cilostazol was associated with a significant reduction in late loss in BMS (mean difference 0." | 3.84 | Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. ( Chen, KY; Chetcuti, S; Grossman, MP; Gurm, H; Meier, P; Rha, SW; Tamhane, U, 2009) |
| "We evaluate the anti-platelet and anti-thrombotic effects of cilostazol using Multiplate® and PFA-100® in vitro and ex vivo with freshly isolated rat whole blood and in vivo venous and arterial thrombosis models in the same species, in an effort to assess the sensitivity of the whole blood aggregometer assays without potential issues of species differences." | 3.77 | Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100® and Multiplate® whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo. ( Bae, IH; Chung, JH; Jeong, YS; Kim, CW; Lim, KM; Park, JW; Park, YH; Yun, JW, 2011) |
| "One possible cause of stent thrombosis is an insufficient effect of clopidogrel." | 3.77 | Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. ( Behr, T; Behr, W; Kuch, B; von Scheidt, W, 2011) |
| "The purpose of this study was to investigate the efficacy of cilostazol for prevention of thrombosis in microsurgical anastomosis." | 3.76 | Cilostazol effectively reduces the decrease of flow volume in a thrombotic anastomosis model in a rat: a novel application of ultrasonography for evaluation. ( Chang, HW; Choi, TH; Han, K; Kim, JH; Kim, SH; Lee, SY; Park, J; Park, SH; Son, D; Suh, EH, 2010) |
| "These results suggest that oral administration of cilostazol is an effective method of preventing thrombotic occlusion and intimal hyperplasia after stenting." | 3.69 | Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. ( Kichikawa, K; Kimura, Y; Kubota, Y; Maeda, M; Makutani, S; Nishimine, K; Ohishi, H; Sakaguchi, S; Uchida, H; Yoshioka, T, 1995) |
| " Pharmacokinetics and pharmacodynamic (antithrombotic) efficacy were evaluated in beagle dog model of arterial thrombosis." | 2.79 | Preparation and evaluation of oral controlled-release cilostazol formulation: pharmacokinetics and antithrombotic efficacy in dogs and healthy male Korean participants. ( Park, JW; Shin, KH; Yoon, G; Yoon, IS, 2014) |
| " Major adverse cardiovascular events, stent thrombosis, target lesion revascularization (TLR), target vessel revascularization, and bleeding events were analyzed after 1-year follow-up." | 2.78 | Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. ( Gao, W; Ge, H; Guo, Y; Zhang, Q; Zhou, Z, 2013) |
| " Cilostazol-based TAPT compared with DAPT is associated with improved angiographic outcomes and decreased risk of TLR and TVR but does not reduce major cardiovascular events and is associated with an increase in minor adverse events." | 2.52 | Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. ( Bai, J; Chen, J; Chen, P; Eikelboom, JW; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Xu, L; Yang, Z; Zou, F, 2015) |
| "Since antiplatelet therapy in type 2 diabetes mellitus (T2DM) patients is very important after intracoronary stenting, and because the most commonly used therapies have been the dual antiplatelet therapy (DAPT) consisting of aspirin and clopidogrel and the triple antiplatelet therapy (TAPT) consisting of aspirin, clopidogrel and cilostazol, we aim to compare the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in T2DM patients." | 2.52 | Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. ( Bundhun, PK; Chen, MH; Qin, T, 2015) |
| "In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb." | 2.50 | Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014) |
| "These platelets enhance thrombus formation at the sites of endothelial disruption." | 2.43 | Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. ( Goto, S, 2005) |
| "Cilostazol effects were also shown in aspirin-treated platelets." | 1.48 | Impact of Multidrug Resistance Protein-4 Inhibitors on Modulating Platelet Function and High on-Aspirin Treatment Platelet Reactivity. ( Alemanno, L; Angiolillo, DJ; Frati, L; Guarino, ML; Klaus, V; Maltese, T; Massimi, I; Pulcinelli, FM, 2018) |
| "Cilostazol has potential for protecting vessels against hyperglycemic injury and for accelerating the healing process after implantation of DES." | 1.39 | Cilostazol protects vessels against hyperglycemic injury and accelerates healing after implantation of drug-eluting stent in a type 1 diabetes mellitus rat aorta stent model. ( Ahn, Y; Cho, HH; Hong, MH; Jeong, HY; Jeong, MH; Kang, WS; Kee, HJ; Kim, YS; Kwon, JS, 2013) |
| "Cilostazol is an anti-platelet drug that reversibly inhibits phosphodiesterase III (PDE-III), which is ubiquitously expressed in platelets and various tissues." | 1.38 | Cilostazol down-regulates the height of mural platelet thrombi formed under a high-shear rate flow in the absence of ADAMTS13 activity. ( Fujimura, Y; Hayakawa, M; Matsumoto, M; Shida, Y; Sugimoto, M; Tsubaki, K; Wada, H; Yagi, H; Yamaguchi, N, 2012) |
| "Cilostazol has reduced restenosis and repeat intervention after drug-eluting stent (DES) implantation." | 1.36 | Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). ( Hong, MK; Kim, JJ; Kim, WJ; Kim, YH; Lee, CW; Lee, JY; Lee, SW; Park, DW; Park, SJ; Park, SW; Yun, SC, 2010) |
| "Ratios of red thrombus to prosthetic graft area were 0." | 1.35 | Effects of cilostazol and k-134 on reconstructive surgery using prosthetic grafts in the abdominal aorta of beagle dogs. ( Inoue, Y; Iwai, T; Jibiki, M; Kudo, T; Sugano, N, 2008) |
| " At 7 and 30 days, the composite outcome for the group treated with cilostazol alone and that treated with abciximab in combination with cilostazol did not differ significantly." | 1.34 | Efficacy and safety of abciximab in combination with cilostazol in patients undergoing stenting. ( Hong, EH; Kim, MY; Lee, MH; Oh, JM; Park, JE; Shin, WG, 2007) |
| "Z-335 (0." | 1.31 | Z-335, a new thromboxane A(2) receptor antagonist, prevents arterial thrombosis induced by ferric chloride in rats. ( Kurimoto, T; Sato, R; Tanaka, T, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.57) | 18.7374 |
| 1990's | 3 (5.36) | 18.2507 |
| 2000's | 17 (30.36) | 29.6817 |
| 2010's | 32 (57.14) | 24.3611 |
| 2020's | 2 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Koga, Y | 1 |
| Kihara, Y | 1 |
| Okada, M | 1 |
| Inoue, Y | 2 |
| Tochizawa, S | 1 |
| Toga, K | 1 |
| Tachibana, K | 1 |
| Kimura, Y | 4 |
| Nishi, T | 1 |
| Hidaka, H | 1 |
| Can Depboylu, B | 1 |
| Yazman, S | 1 |
| Harmandar, B | 1 |
| Funda Tetik, M | 1 |
| Istar, H | 1 |
| Arslan, K | 1 |
| Ilhan, G | 1 |
| Bartholomew, J | 1 |
| Bishop, GJ | 1 |
| Rychter, M | 1 |
| Baranowska-Korczyc, A | 1 |
| Milanowski, B | 1 |
| Jarek, M | 1 |
| Maciejewska, BM | 1 |
| Coy, EL | 1 |
| Lulek, J | 1 |
| Alemanno, L | 1 |
| Massimi, I | 1 |
| Klaus, V | 1 |
| Guarino, ML | 1 |
| Maltese, T | 1 |
| Frati, L | 1 |
| Angiolillo, DJ | 2 |
| Pulcinelli, FM | 1 |
| Huang, F | 1 |
| Ikeda, Y | 1 |
| Yamanouchi, J | 1 |
| Kumon, Y | 1 |
| Yasukawa, M | 1 |
| Hato, T | 1 |
| Kwon, JS | 1 |
| Kim, YS | 1 |
| Cho, HH | 1 |
| Kee, HJ | 1 |
| Hong, MH | 1 |
| Kang, WS | 1 |
| Jeong, HY | 1 |
| Jeong, MH | 1 |
| Ahn, Y | 1 |
| Shin, KH | 1 |
| Yoon, G | 1 |
| Yoon, IS | 1 |
| Park, JW | 2 |
| Chen, J | 1 |
| Meng, H | 1 |
| Xu, L | 1 |
| Liu, J | 1 |
| Kong, D | 1 |
| Chen, P | 1 |
| Gong, X | 1 |
| Bai, J | 1 |
| Zou, F | 1 |
| Yang, Z | 1 |
| Li, C | 1 |
| Eikelboom, JW | 2 |
| Di Minno, G | 1 |
| Spadarella, G | 1 |
| Cafaro, G | 1 |
| Petitto, M | 1 |
| Lupoli, R | 1 |
| Di Minno, A | 1 |
| de Gaetano, G | 1 |
| Tremoli, E | 1 |
| Bundhun, PK | 1 |
| Qin, T | 1 |
| Chen, MH | 1 |
| Kim, JY | 1 |
| Choi, YS | 1 |
| Kwon, A | 1 |
| Chung, WB | 1 |
| Park, CS | 1 |
| Kim, HY | 1 |
| Chang, K | 1 |
| Lee, MY | 1 |
| Chung, WS | 1 |
| Seung, KB | 1 |
| Sugano, N | 1 |
| Jibiki, M | 1 |
| Kudo, T | 1 |
| Iwai, T | 1 |
| Arai, F | 1 |
| Kita, T | 1 |
| Sasaki, S | 1 |
| Onoda, K | 1 |
| Ohashi, K | 1 |
| Hashimoto, A | 1 |
| Okuda, M | 1 |
| Shimono, T | 1 |
| Nishikawa, M | 2 |
| Shimpo, H | 1 |
| Ryu, KH | 1 |
| Han, HY | 1 |
| Lee, SY | 4 |
| Jeon, SD | 1 |
| Im, GJ | 1 |
| Lee, BY | 1 |
| Kim, K | 1 |
| Lim, KM | 2 |
| Chung, JH | 2 |
| Tamhane, U | 1 |
| Meier, P | 1 |
| Chetcuti, S | 1 |
| Chen, KY | 1 |
| Rha, SW | 1 |
| Grossman, MP | 1 |
| Gurm, H | 1 |
| Yasuda, H | 1 |
| Yamada, M | 1 |
| Sawada, S | 1 |
| Endo, Y | 1 |
| Inoue, K | 1 |
| Asano, F | 1 |
| Takeyama, Y | 1 |
| Yoshiba, M | 1 |
| Lee, SW | 3 |
| Park, SW | 3 |
| Yun, SC | 1 |
| Kim, YH | 3 |
| Park, DW | 1 |
| Kim, WJ | 1 |
| Lee, JY | 1 |
| Lee, CW | 3 |
| Hong, MK | 3 |
| Kim, JJ | 3 |
| Park, SJ | 3 |
| Croce, K | 1 |
| Kim, SH | 2 |
| Chang, HW | 1 |
| Choi, TH | 1 |
| Kim, JH | 2 |
| Son, D | 1 |
| Han, K | 1 |
| Park, J | 1 |
| Suh, EH | 1 |
| Park, SH | 1 |
| Weber, R | 1 |
| Diener, HC | 1 |
| Lin, GM | 1 |
| Chu, KM | 1 |
| Han, CL | 1 |
| Jeong, YH | 3 |
| Park, Y | 3 |
| Kim, IS | 3 |
| Yun, SE | 2 |
| Kang, MK | 1 |
| Hwang, SJ | 2 |
| Kwak, CH | 2 |
| Hwang, JY | 2 |
| Kim, CW | 1 |
| Yun, JW | 1 |
| Bae, IH | 1 |
| Park, YH | 2 |
| Jeong, YS | 1 |
| Park, KS | 1 |
| Park, JR | 1 |
| Koh, EH | 1 |
| Kim, S | 1 |
| Behr, T | 1 |
| Kuch, B | 1 |
| Behr, W | 1 |
| von Scheidt, W | 1 |
| Gresele, P | 1 |
| Momi, S | 1 |
| Falcinelli, E | 1 |
| Bliden, KP | 1 |
| Tantry, US | 1 |
| Gurbel, PA | 1 |
| Ferreiro, JL | 1 |
| Ueno, M | 1 |
| Desai, B | 1 |
| Capranzano, P | 1 |
| Capodanno, D | 1 |
| Pant, S | 1 |
| Neupane, P | 1 |
| Ramesh, KC | 1 |
| Barakoti, M | 1 |
| Hirsh, J | 1 |
| Spencer, FA | 1 |
| Baglin, TP | 1 |
| Weitz, JI | 1 |
| Porto, I | 1 |
| D'Amario, D | 1 |
| Crea, F | 1 |
| Sidddiqi, SA | 1 |
| Kamal, AK | 1 |
| Hondo, T | 1 |
| Matsumura, H | 1 |
| Matsuda, K | 1 |
| Iwamoto, A | 1 |
| Eno, S | 1 |
| Kimura, M | 1 |
| Ashitate, Y | 1 |
| Tanaka, E | 1 |
| Henary, M | 1 |
| Choi, HS | 1 |
| Frangioni, JV | 1 |
| Flaumenhaft, R | 2 |
| Yamada, K | 1 |
| Niki, H | 1 |
| Nagai, H | 1 |
| Nakagawa, H | 1 |
| Yagi, H | 1 |
| Yamaguchi, N | 1 |
| Shida, Y | 1 |
| Hayakawa, M | 1 |
| Matsumoto, M | 1 |
| Sugimoto, M | 1 |
| Wada, H | 1 |
| Tsubaki, K | 1 |
| Fujimura, Y | 1 |
| Lee, GY | 1 |
| Hahn, JY | 1 |
| Kim, HJ | 1 |
| Song, YB | 1 |
| Choi, SH | 1 |
| Choi, JH | 1 |
| Gwon, HC | 1 |
| Gao, W | 1 |
| Zhang, Q | 1 |
| Ge, H | 1 |
| Guo, Y | 1 |
| Zhou, Z | 1 |
| Sim, DS | 1 |
| Merrill-Skoloff, G | 1 |
| Furie, BC | 1 |
| Furie, B | 1 |
| Ahn, JC | 1 |
| Song, WH | 1 |
| Kwon, JA | 1 |
| Park, CG | 1 |
| Seo, HS | 1 |
| Oh, DJ | 1 |
| Rho, YM | 1 |
| Park, JH | 1 |
| Kang, SJ | 1 |
| Han, KH | 2 |
| Kawata, M | 1 |
| Kuramoto, E | 1 |
| Kataoka, T | 1 |
| Saito, A | 1 |
| Adachi, K | 1 |
| Matsuura, A | 1 |
| Sakamoto, S | 1 |
| Massel, D | 1 |
| Goto, S | 2 |
| Lee, BK | 1 |
| Song, JM | 1 |
| Kang, DH | 1 |
| Song, JK | 1 |
| Meadows, TA | 1 |
| Bhatt, DL | 1 |
| Hong, EH | 1 |
| Kim, MY | 1 |
| Park, JE | 1 |
| Lee, MH | 1 |
| Oh, JM | 1 |
| Shin, WG | 1 |
| Kubota, Y | 1 |
| Kichikawa, K | 1 |
| Uchida, H | 1 |
| Maeda, M | 1 |
| Nishimine, K | 1 |
| Makutani, S | 1 |
| Sakaguchi, S | 1 |
| Yoshioka, T | 1 |
| Ohishi, H | 1 |
| Kohda, N | 1 |
| Tani, T | 2 |
| Nakayama, S | 1 |
| Adachi, T | 1 |
| Marukawa, K | 1 |
| Ito, R | 1 |
| Ishida, K | 1 |
| Matsumoto, Y | 1 |
| Tanaka, T | 1 |
| Sato, R | 1 |
| Kurimoto, T | 1 |
| Kanbe, T | 1 |
| Watanabe, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| "Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"[NCT02513004] | Phase 4 | 60 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for cilostazol and Blood Clot
| Article | Year |
|---|---|
Stent thrombosis associated with drug eluting stents on addition of cilostazol to the standard dual antiplatelet therapy following percutaneous coronary intervention: a systematic review and meta-analysis of published randomized controlled trials.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Percutaneo | 2018 |
Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; M | 2015 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int | 2014 |
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitu | 2015 |
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis | 2009 |
Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.
Topics: Aspirin; Blood-Brain Barrier; Cilostazol; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy | 2010 |
Anti-platelet therapy: phosphodiesterase inhibitors.
Topics: Blood Platelets; Cilostazol; Clinical Trials as Topic; Dipyridamole; Humans; Phosphodiesterase Inhib | 2011 |
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Aspirin; Cilostazol; Dipyridamole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Evid | 2012 |
Cilostazol and primary-PCI: mirage or good alternative?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Aspirin; Cilostazol; | 2012 |
Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding.
Topics: Bleeding Time; Cilostazol; Dose-Response Relationship, Drug; Hemorrhage; Humans; Platelet Aggregatio | 2005 |
[Basic principal of the dual antithrombotic therapy achieved by cilostazol].
Topics: Cilostazol; Hemorrhage; Humans; Phosphodiesterase Inhibitors; Tetrazoles; Thrombosis; Vasodilator Ag | 2006 |
Clinical aspects of platelet inhibitors and thrombus formation.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Cardiovascular Diseases; Cilostazol; Clopidogrel; Dipyrid | 2007 |
9 trials available for cilostazol and Blood Clot
| Article | Year |
|---|---|
Preparation and evaluation of oral controlled-release cilostazol formulation: pharmacokinetics and antithrombotic efficacy in dogs and healthy male Korean participants.
Topics: Administration, Oral; Animals; Cilostazol; Delayed-Action Preparations; Disease Models, Animal; Dogs | 2014 |
Inhibition of platelet aggregation by combined therapy with aspirin and cilostazol after off-pump coronary artery bypass surgery.
Topics: Aged; Aspirin; Cilostazol; Coronary Artery Bypass, Off-Pump; Drug Therapy, Combination; Female; Fibr | 2008 |
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis | 2009 |
Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; F | 2010 |
Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; | 2011 |
Adjunctive cilostazol versus high maintenance dose of clopidogrel in patients with hyporesponsiveness to chronic clopidogrel therapy.
Topics: Adult; Aged; Blood Platelets; Cilostazol; Clopidogrel; Cross-Over Studies; Drug Administration Sched | 2013 |
Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; H | 2013 |
Comparison of cilostazol and clopidogrel after successful coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Female; | 2005 |
Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention.
Topics: Aged; Aspirin; Cilostazol; Drug Therapy, Combination; Female; Humans; Incidence; Male; Myocardial In | 2005 |
36 other studies available for cilostazol and Blood Clot
| Article | Year |
|---|---|
2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities.
Topics: Animals; Arteriosclerosis; Cilostazol; Hyperplasia; Platelet Aggregation Inhibitors; Quinolines; Qui | 1998 |
Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol?
Topics: Atherosclerosis; Cilostazol; Diabetic Angiopathies; Humans; Peripheral Arterial Disease; Quality of | 2023 |
New treatments for peripheral artery disease.
Topics: Ankle Brachial Index; Anticholesteremic Agents; Cilostazol; Diet, Healthy; Dual Anti-Platelet Therap | 2020 |
Cilostazol-Loaded Poly(ε-Caprolactone) Electrospun Drug Delivery System for Cardiovascular Applications.
Topics: Atherosclerosis; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cilostazol; Drug Com | 2018 |
Impact of Multidrug Resistance Protein-4 Inhibitors on Modulating Platelet Function and High on-Aspirin Treatment Platelet Reactivity.
Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Cohort Studies; Cyclic AMP; Female; Humans; Male; Middle | 2018 |
Association of platelet response to cilostazol with clinical outcome and CYP genotype in patients with cerebral infarction.
Topics: Aged; Cell Adhesion Molecules; Cerebral Infarction; Cilostazol; Cytochrome P-450 CYP2C19; Cytochrome | 2018 |
Cilostazol protects vessels against hyperglycemic injury and accelerates healing after implantation of drug-eluting stent in a type 1 diabetes mellitus rat aorta stent model.
Topics: Administration, Oral; Angioplasty, Balloon; Animals; Aorta; Aortic Diseases; Apoptosis; Blood Glucos | 2013 |
It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent.
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Evero | 2015 |
Effects of cilostazol and k-134 on reconstructive surgery using prosthetic grafts in the abdominal aorta of beagle dogs.
Topics: Animals; Aorta, Abdominal; Blood Vessel Prosthesis Implantation; Cilostazol; Male; Mice; Plastic Sur | 2008 |
[Perioperative management of patients with drug-eluting coronary stents presenting for non-cardiac surgery].
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cilostazol; Drug Administration Schedule; Drug-Elu | 2008 |
Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time.
Topics: Animals; Bleeding Time; Blood Coagulation; Cells, Cultured; Cilostazol; Drug Synergism; Fibrinolytic | 2009 |
Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Co | 2009 |
Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up | 2010 |
Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?".
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chemotherapy, Adjuvant; Cilostazol; C | 2010 |
Cilostazol effectively reduces the decrease of flow volume in a thrombotic anastomosis model in a rat: a novel application of ultrasonography for evaluation.
Topics: Anastomosis, Surgical; Animals; Cilostazol; Disease Models, Animal; Iliac Artery; Male; Microsurgery | 2010 |
Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Myocardial | 2010 |
Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100® and Multiplate® whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo.
Topics: Animals; Blood Platelets; Chlorides; Cilostazol; Ferric Compounds; Fibrinolytic Agents; Male; Mice; | 2011 |
Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cerebrovascula | 2011 |
We need further studies for the development of "optimized antiplatelet therapy" based on ethnicity.
Topics: Administration, Oral; Alleles; Aryl Hydrocarbon Hydroxylases; Asian People; Blood Platelets; Cilosta | 2011 |
Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus.
Topics: Aspirin; Blood Coagulation; Blood Platelets; Cilostazol; Clopidogrel; Diabetes Mellitus, Type 2; Hum | 2012 |
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistan | 2011 |
A new antiplatelet agent cilostazol--what is the evidence for its use and tolerability?
Topics: Aspirin; Cilostazol; Evidence-Based Medicine; Humans; Platelet Aggregation Inhibitors; Randomized Co | 2012 |
A case of acute coronary artery occlusion associated with very rapid onset heparin-induced thrombosis without thrombocytopenia.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Aspirin; Autoantibodies | 2012 |
Two-wavelength near-infrared fluorescence for the quantitation of drug antiplatelet effects in large animal model systems.
Topics: Analysis of Variance; Animals; Aspirin; Blood Platelets; Cilostazol; Disease Models, Animal; Female; | 2012 |
Serotonin potentiates high-glucose-induced endothelial injury: the role of serotonin and 5-HT(2A) receptors in promoting thrombosis in diabetes.
Topics: Animals; Aspirin; Cells, Cultured; Cilostazol; Diabetes Mellitus, Experimental; Fibrinolytic Agents; | 2012 |
Cilostazol down-regulates the height of mural platelet thrombi formed under a high-shear rate flow in the absence of ADAMTS13 activity.
Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Biomechanical Phenomena; Bleeding Time; Blood Platelets; Cil | 2012 |
Initial accumulation of platelets during arterial thrombus formation in vivo is inhibited by elevation of basal cAMP levels.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Platelets; Cilostazol; Cyclic AMP; Cyclic Nucleo | 2004 |
Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel.
Topics: Aspirin; Cilostazol; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Femal | 2004 |
P >0.05 not equal equivalent or noninferior.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Re | 2005 |
Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Humans; Male; | 2005 |
Efficacy and safety of abciximab in combination with cilostazol in patients undergoing stenting.
Topics: Abciximab; Aged; Angina, Unstable; Antibodies, Monoclonal; Cilostazol; Coronary Angiography; Coronar | 2007 |
Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study.
Topics: Administration, Oral; Animals; Arterial Occlusive Diseases; Cilostazol; Dogs; Embolization, Therapeu | 1995 |
Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Carotid Arteries; Cilostazol; Cyclic Nucleotide Phosph | 1999 |
Z-335, a new thromboxane A(2) receptor antagonist, prevents arterial thrombosis induced by ferric chloride in rats.
Topics: Administration, Oral; Animals; Aorta, Abdominal; Chlorides; Cilostazol; Dose-Response Relationship, | 2000 |
New antithrombotic agent, cilostazol.
Topics: Animals; Azoles; Cilostazol; Fibrinolytic Agents; Humans; Tetrazoles; Thrombosis; Vasodilator Agents | 1985 |
Effect of cilostazol on platelet aggregation and experimental thrombosis.
Topics: Adenosine Diphosphate; Animals; Aspirin; Azoles; Cilostazol; Dogs; Fibrinolytic Agents; Humans; In V | 1985 |